| 1 |
Guyatt GH, Oxman AD, Vist GE, et al. Rating quality of evidence and strength of recommendations: GRADE: an emerging consensus on rating quality of evidence and strength of recommendations[J]. BMJ,2008,336(7650):924.
|
| 2 |
Shiffman RN, Shekelle P, Overhage JM, et al. Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization[J]. Ann Intern Med,2003,139(6):493-498.
|
| 3 |
Mak LY, Seto WK, Lai CL, et al. DNA polymerase inhibitors for treating hepatitis B: a safety evaluation[J]. Expert opinion on drug safety,2016,15(3):383-392.
|
| 4 |
曲云东，叶茜，王磊, 等. 39例阿德福韦酯相关肾性低磷血症及骨软化症临床分析和初步转归[J]. 中华传染病杂志,2015,33(11):678-681.
|
| 5 |
Fisher EJ, Chaloner K, Cohn DL, et al. The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial[J]. AIDS,2001,15(13):1695-1700.
|
| 6 |
Gara N, Zhao X, Collins MT, et al. Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B[J]. Aliment Pharmacol Ther,2012,35(11):1317-1325.
|
| 7 |
Izzedine H, Hulot JS, Launay-Vacher V, et al. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies[J]. Kidney Int,2004,66(3):1153-1158.
|
| 8 |
Mallet V, Schwarzinger M, Vallet-Pichard A, et al. Effect of nucleoside and nucleotide analogues on renal function in patients with chronic hepatitis B virus monoinfection[J]. Clin Gastroenterol Hepatol,2015,13(6):1181-1188. e1.
|
| 9 |
Koklu S, Gulsen MT, Tuna Y, et al. Differences in nephrotoxicity risk and renal effects among anti-viral therapies against hepatitis B[J]. Aliment Pharmacol Ther,2015,41(3):310-319.
|
| 10 |
Gish R, Mangahas M, Baqai S, et al. Risk of renal toxicity with tenofovir DF for chronic hepatitis B[J]. J Hepatol,2010,52(10):S388-S389.
|
| 11 |
朱菡，袁欣，唐琳, 等. 阿德福韦酯致范可尼综合征2例分析[J]. 中华肝脏病杂志,2015,23(4):302-303.
|
| 12 |
Law ST, Li KK, Ho YY. Acquired fanconi syndrome associated with prolonged adefovir dipivoxil therapy in a chronic hepatitis B patient[J]. Am J Ther,2013,20(6):e713-e716.
|
| 13 |
王艳艳，程虹，王国勤, 等. 阿德福韦酯致范可尼综合征一例[J]. 中华肾脏病杂志,2012,28(7):578.
|
| 14 |
杜培洁，邵明玮，黄婷, 等. 阿德福韦酯致获得性范可尼综合征一例[J]. 中华肾脏病杂志,2012,28(8):665.
|
| 15 |
Gracey DM, Snelling P, McKenzie P, et al. Tenofovir-associated Fanconi syndrome in patients with chronic hepatitis B monoinfection[J]. Antivir Ther,2013,18(7):945-948.
|
| 16 |
Samarkos M, Theofanis V, Eliadi I, et al. Tenofovir-associated fanconi syndrome in a patient with chronic hepatitis B[J]. J Gastrointestin Liver Dis,2014,23(3):342.
|
| 17 |
Hwang HS, Park CW, Song MJ. Tenofovir-associated fanconi syndrome and nephrotic syndrome in a patient with chronic hepatitis B monoinfection[J]. Hepatology,2015,62(4):1318-1320.
|
| 18 |
Vigano M, Brocchieri A, Spinetti A, et al. Tenofovirinduced fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal[J]. J Clin Virol,2014,61(4):600-603.
|
| 19 |
Gane E, Deray G, Liaw YF, et al. Telbivudine improves renal function in patients with chronic hepatitis B[J]. Gastroenterology,2014,146(1):138-146.
|
| 20 |
Lee M, Oh S, Lee HJ, et al. Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy[J]. J Viral Hepat,2014,21(12):873-881.
|
| 21 |
Qi X, Wang J, Zhang J, et al. Impact of nucleos(t)ide analogue combination therapy on the estimated glomerular filtration rate in patients with chronic hepatitis B[J]. Medicine (Baltimore),2015,94(15):e646-e646.
|
| 22 |
Bedimo R, Maalouf N, Zhang S, et al. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents[J]. AIDS,2012,26(7):825-831.
|
| 23 |
Gill US, Al-Shamma S, Burke K, et al. Factors determining bone mineral density loss in chronic hepatitis B patients: is tenofovir disoproxil fumarate the main culprit?[J]. J Hepatol,2011,54(9):S286-S286.
|
| 24 |
Wong GL, Choi KK, Chan HL, et la. Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: A cohort study of 53 500 subjects[J]. Hepatology,2015,62(3):684-693.
|
| 25 |
Matthew SJ. Telbivudine for the management of chronic hepatitis B virus infection[J]. Clin Ther,2007;29(12):2635-2653.
|
| 26 |
Liaw YF, Gane E, Leung N, et al. 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B[J]. Gastroenterology,2009,136(2):486-495.
|
| 27 |
Wang Y, Thongsawat S, Gane E, et al. Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B[J]. J Viral Hep,2013,20(4):e37-e46.
|
| 28 |
Wang M, Da Y, Cai H, et al. Telbivudine myopathy in a patient with chronic hepatitis B[J]. Inter J Clin Pharm,2012,34(3):422-425.
|
| 29 |
曾俊涛，陈静，郭峰. 替比夫定致横纹肌溶解症一例[J]. 海南医学,2010,21(23):133.
|
| 30 |
Zou XJ, Jiang XQ, Tian DY, et al. Clinical features and risk factors of creatine kinase elevations and myopathy associated with telbivudine[J]. J Viral Hep,2011,18(12):892-896.
|
| 31 |
Finsterer J, Ay L. Myotoxicity of telbivudine in pre-existing muscle damage[J]. J Virol,2010,7(1):1-3.
|
| 32 |
Goncalves J, Laeufle R, Avila C. Increased risk with combination of telbivudine and pegylated-interferon alfa-2a in study CLDT600A2406, compared to uncommon rate with telbivudine monotherapy from the Novartis global database[J]. J. Hepatol,2009,50(9):S329-S330.
|
| 33 |
Marcellin P, Avila C, Wursthorn K, et al. Telbivudine plus peg-interferon in HbeAg-positive chronic hepatitis B--very potent antiviral efficacy but risk of peripheral neuropathy[J]. J Hepatol,2010,52(10):S6-S7.
|
| 34 |
Marcellin P, Wursthorn K, Wedemeyer H, et al. Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy[J]. J Hepatol,2015,62(1):41-47.
|
| 35 |
Fodale V, Mazzeo A, Pratico C, et al. Fatal exacerbation of peripheral neuropathy during lamivudine therapy: evidence for iatrogenic mitochondrial damage[J]. Anaesthesia,2005,60(8):806-810.
|
| 36 |
Xu HL, Wang ZX, Zheng LM, et al. Lamivudine/telbivudine associated neuromyopathy: neurogenic damage, mitochondrial dysfunction and mitochondrial DNA depletion[J]. J Clin Pathol,2014,67(11):999-1005.
|
| 37 |
Lange CM, Bojunga J, Hofmann WP, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function[J]. J Hepatol,2009,50(6):2001-2006.
|
| 38 |
Cohen SM, Levy RM, Jovanovich JF, et al. Fatal lactic acidosis associated with the use of combination oral medications to treat reactivation of hepatitis B[J]. J Clin Gastroenterol,2009,43(10):1008-1010.
|
| 39 |
Jin JL, Hu P, Lu JH, et al. Lactic acidosis during telbivudine treatment for HBV: A case report and literature review[J]. World J Gastroenterol,2013,19(33):5575-5580.
|
| 40 |
任江波，王宇，李红艺, 等. 替比夫定治疗慢性乙型肝炎期间肌酸激酶升高的观察与分析[J]. 中华肝脏病杂志,2012,20(9):641-643.
|
| 41 |
中华医学会肝病学分会，中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年版)[J/CD]. 中国肝脏病杂志:电子版,2015,8(3):1-18.
|
| 42 |
参加乙型肝炎病毒耐药讨论专家委员会. 核苷和核苷酸类药物治疗慢性乙型肝炎的耐药及其管理[J/CD]. 中华实验和临床感染病杂志:电子版,2012,6(6):643-650.
|